Status:
RECRUITING
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Lead Sponsor:
Pierre Fabre Pharma GmbH
Collaborating Sponsors:
iOMEDICO AG
Pierre Fabre Pharma AG
Conditions:
Metastatic Colorectal Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 month...
Detailed Description
The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 month...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
September 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04673955
Start Date
September 3 2020
End Date
January 1 2027
Last Update
September 29 2022
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinic
Braunau am Inn, Upper Austria, Austria, 5280
2
Clinic
Linz, Upper Austria, Austria, 4010
3
Clinic
Feldkirch, Voralberg, Austria, 6807
4
Clinic
Vienna, Austria, 1090